EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

May 14, 2021

Study Completion Date

May 14, 2021

Conditions
Stomatitis
Interventions
DRUG

EC-18

Oral administration of EC-18 twice daily

DRUG

Placebo

Placebo to match EC-18 capsule administration

Trial Locations (20)

10003

Mount Sinai - Union Square, New York

18045

St. Luke's Cancer Center - Anderson Campus, Easton

21204

Greater Baltimore Medical Center, Baltimore

30322

Winship Cancer Institute of Emory University, Atlanta

33140

Mount Sinai Comprehensive Cancer Center, Miami Beach

33176

Miami Cancer Institute, Miami

40536

University of Kentucky, Chandler Medical Center, CCTS, Lexington

60201

NorthShore University HealthSystem, Evanston

62702

Southern Illinois University School of Medicine, Springfield

67214

Cancer Center of Kansas, Wichita

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75701

Hope Cancer Center of East Texas, Tyler

76712

Baylor Scott & White Medical Center - Hillcrest, Waco

90095

UCLA Jonsson Comprehensive Cancer Center, Los Angeles

90822

Veterans Affairs Long Beach Health Care System, Long Beach

97239

Oregon Health and Science University, Portland

VA Portland HealthCare System, Portland

98405

MultiCare Institute for Research and Innovation, Spokane

MultiCare Institute for Research and Innovation, Tacoma

63110-1010

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Enzychem Lifesciences Corporation

INDUSTRY